Table 1 Transplantation outcomes
Outcomes | Total cohort (N=27) | FLU+CY/MEL+TBI without ATG (n=11) | Other regimens (n=16) | P-value |
|---|---|---|---|---|
Engraftment, n (%) | 0.005 | |||
Sustained engraftment | 18 (67) | 11 (100) | 7 (44) | |
Primary GF | 8 (30) | 0 | 8 (50) | |
Secondary GF | 1 (4) | 0 | 1 (6) | |
Acute GVHD, n | 1 | |||
No | 9 | 4 | 5 | |
Yes (I/II/III/IV/ND) | 15 (7/4/1/1/2) | 6 (4/2/0/0/0) | 9 (3/2/1/1/2) | |
Unknown | 3 | 0 | 3 | |
Chronic GVHD, n | 1 | |||
None | 16 | 9 | 7 | |
Yes (limited/extensive) | 4 (2/2) | 2 (1/1) | 2 (1/1) | |
Unknown | 7 | 0 | 7 | |
CMV reactivation, n | 0.065 | |||
Yes/No/Unknown | 9/11/7 | 6/2/3 | 3/9/4 | |
CMV disease, n | 1 | |||
Yes/No/Unknown | 2/24/1 | 1/10/0 | 1/14/1 | |
Secondary malignancies, n | 1 | |||
Yes/No | 1/26 | 0/11 | 1/15 | |
Survival, n | 0.008 | |||
Alive/dead | 19/8 | 11/0 | 8/8 | |
5-year failure-free survival, % (95% CI) | 59.3% (38.6–75.0%) | 100% (100–100%) | 31.2 (11.4–53.6%) | <0.001 |
5-year overall survival, (95% CI) | 69.5% (48.1–83.5%) | 100% (100–100%) | 48.6 (22.9–70.3%) | 0.007 |
